UNCY
Unicycive Therapeutics, Inc.Healthcare · $99M market cap
Verdict
We can't put a fair value on UNCY right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow UNCY
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 28, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about UNCY
Are insiders buying UNCY?
Since Oct 28, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar).
How can I check UNCY's value myself?
Use the free Sticker Price calculator, already filled with UNCY's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 29, 2026. How the Payback Price works